首页> 外文期刊>Bioconjugate Chemistry >Synthesis and in Vitro Testing of J591 Antibody-Dendrimer Conjugates for Targeted Prostate Cancer Therapy
【24h】

Synthesis and in Vitro Testing of J591 Antibody-Dendrimer Conjugates for Targeted Prostate Cancer Therapy

机译:J591抗体-Dendrimer偶联物用于前列腺癌靶向治疗的合成及体外测试

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Targeted therapeutics using antibodies are an attractive option over conventional cancer chemothera-peutics due to their potential to deliver a therapeutic specifically to cancer tissue without damaging normal tissue.However,there are known problems with immunoconjugates such as decreased inimunoreactivity and poor solubility.Using dendrimers as carriers for these agents has the potential to resolve these issues.We synthesized J591 anti-PSMA(prostate specific membrane antigen)antibody dendrimer conjugates containing fluorophores on the dendrimer.The in vitro studies of these conjugates show that they specifically bind to cells expressing PSMA.Confocal microscopy experiments document the binding and internalization of these conjugates.This research encourages the further study of antibody-dendrimer-drug conjugates for use in targeted therapeutics.
机译:使用抗体的靶向疗法是常规癌症化疗药物的诱人选择,因为它们具有将疗法特异性地递送至癌组织而不损害正常组织的潜力。然而,免疫偶联物存在已知的问题,例如免疫反应性降低和溶解性差。这些试剂的载体具有解决这些问题的潜力。我们合成了在树枝状聚合物上含有荧光团的J591抗PSMA(前列腺特异性膜抗原)抗体树枝状聚合物缀合物。这些缀合物的体外研究表明它们与表达PSMA的细胞特异性结合。共聚焦显微镜实验记录了这些结合物的结合和内在化。这项研究鼓励进一步研究抗体-树状大分子-药物结合物用于靶向治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号